Context Therapeutics (NASDAQ:CNTX) and Sandoz Group (OTCMKTS:SDZNY) Head-To-Head Comparison

Sandoz Group (OTCMKTS:SDZNY) and Context Therapeutics (NASDAQ:CNTX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Risk and Volatility

Sandoz Group has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. Comparatively, Context Therapeutics has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Sandoz Group and Context Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sandoz Group	0	2	0	1	2.67
Context Therapeutics	1	0	7	0	2.75

Context Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 289.61%. Given Context Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Context Therapeutics is more favorable than Sandoz Group.

Profitability

This table compares Sandoz Group and Context Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sandoz Group	N/A	N/A	N/A
Context Therapeutics	N/A	-30.93%	-29.59%

Insider and Institutional Ownership

0.1% of Sandoz Group shares are owned by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are owned by institutional investors. 3.0% of Context Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Sandoz Group and Context Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sandoz Group	$10.36 billion	3.27	$1.00 million	N/A	N/A
Context Therapeutics	N/A	N/A	-$26.73 million	($0.24)	-6.42

Sandoz Group has higher revenue and earnings than Context Therapeutics.

Summary

Context Therapeutics beats Sandoz Group on 6 of the 11 factors compared between the two stocks.

About Sandoz Group

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.

About Context Therapeutics

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.